GLPwatch
Papers (10373)
Page 33 of 173, ranked by citation count.
- Liraglutide-induced acute kidney injury.
- Glucagon-like peptide-1 receptor agonist treatment reduces beta cell mass in normoglycaemic mice.
- Sitagliptin and Liraglutide Modulate L-dopa Effect and Attenuate Dyskinetic Movements in Rotenone-Lesioned Rats.
- Semaglutide and Tirzepatide for the Management of Weight Recurrence After Sleeve Gastrectomy: A Retrospective Cohort Study.
- Glucagon-like peptide-1 receptor activation alleviates lipopolysaccharide-induced acute lung injury in mice via maintenance of endothelial barrier function.
- Long-Term Effectiveness of Liraglutide for Weight Management and Glycemic Control in Type 2 Diabetes.
- Efficacy and safety of semaglutide for weight management: evidence from the STEP program.
- Liraglutide prevents hypoadiponectinemia-induced insulin resistance and alterations of gene expression involved in glucose and lipid metabolism.
- Lixisenatide plus basal insulin in patients with type 2 diabetes mellitus: a meta-analysis.
- Liraglutide ameliorates glycometabolism and insulin resistance through the upregulation of GLUT4 in diabetic KKAy mice.
- Efficacy and safety of oral semaglutide in type 2 diabetes mellitus: A systematic review and meta-analysis.
- GSK2374697, a novel albumin-binding domain antibody (AlbudAb), extends systemic exposure of exendin-4: first study in humans--PK/PD and safety.
- Effect of exenatide twice daily and dapagliflozin, alone and in combination, on markers of kidney function in obese patients with type 2 diabetes: A prespecified secondary analysis of a randomized controlled clinical trial.
- Systolic blood pressure reduction with tirzepatide in patients with type 2 diabetes: insights from SURPASS clinical program.
- Combined melatonin and exendin-4 therapy preserves renal ultrastructural integrity after ischemia-reperfusion injury in the male rat.
- Relationship between residual gastric content and peri-operative semaglutide use assessed by gastric ultrasound: a prospective observational study.
- Liraglutide exerts an anti-inflammatory action in obese patients with type 2 diabetes.
- Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy Risk Among Patients With Diabetes.
- Oral Semaglutide Versus Empagliflozin, Sitagliptin and Liraglutide in the UK: Long-Term Cost-Effectiveness Analyses Based on the PIONEER Clinical Trial Programme.
- Glucagon-like Peptide-1 receptor agonist treatment patterns among type 2 diabetes patients in six European countries.
- Improvement of psoriasis during exenatide treatment in a patient with diabetes.
- DA5-CH and Semaglutide Protect against Neurodegeneration and Reduce <i>α</i>-Synuclein Levels in the 6-OHDA Parkinson's Disease Rat Model.
- Radiolabelled GLP-1 analogues for in vivo targeting of insulinomas.
- Efficacy and safety of once-weekly tirzepatide for weight management compared to placebo: An updated systematic review and meta-analysis including the latest SURMOUNT-2 trial.
- Counter-regulatory hormone responses to hypoglycaemia in people with type 1 diabetes after 4 weeks of treatment with liraglutide adjunct to insulin: a randomized, placebo-controlled, double-blind, crossover trial.
- Acute metabolic effects of exenatide in patients with type 1 diabetes with and without residual insulin to oral and intravenous glucose challenges.
- Role of glucagon-like peptide-1 analogue versus amylin as an adjuvant therapy in type 1 diabetes in a closed loop setting with ePID algorithm.
- Normal pregnancy outcome after first-trimester exposure to liraglutide in a woman with Type 2 diabetes.
- Once-weekly semaglutide 7·2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial.
- Exendin-4 induces myocardial protection through MKK3 and Akt-1 in infarcted hearts.
- DPP4 inhibitor vildagliptin preserves β-cell mass through amelioration of endoplasmic reticulum stress in C/EBPB transgenic mice.
- Patient preferences for glucagon-like peptide 1 receptor-agonist treatment attributes.
- Lixisenatide reduces postprandial hyperglycaemia via gastrostatic and insulinotropic effects.
- Molecular and cellular mechanisms of glucagon-like peptide-1 receptor agonist-mediated attenuation of cardiac fibrosis.
- GLP-1 receptor agonists and HBA1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials.
- Beneficial effects of liraglutide on adipocytokines, insulin sensitivity parameters and cardiovascular risk biomarkers in patients with Type 2 diabetes: a prospective study.
- 3-Iodothyronamine: a modulator of the hypothalamus-pancreas-thyroid axes in mice.
- LOX-1, a bridge between GLP-1R and mitochondrial ROS generation in human vascular smooth muscle cells.
- Updates on cardiovascular outcome trials in diabetes.
- Impact of exenatide on mitochondrial lipid metabolism in mice with nonalcoholic steatohepatitis.
- Acute pancreatitis associated with liraglutide.
- Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study.
- Short-term treatment with high dose liraglutide improves lipid and lipoprotein profile and changes hormonal mediators of lipid metabolism in obese patients with no overt type 2 diabetes mellitus: a randomized, placebo-controlled, cross-over, double-blind clinical trial.
- Restoration of cerebral and systemic microvascular architecture in APP/PS1 transgenic mice following treatment with Liraglutide™.
- Glucagon-like peptide-1 receptor agonist, semaglutide attenuates chronic liver disease-induced skeletal muscle atrophy in diabetic mice.
- Role of apolipoprotein C-III overproduction in diabetic dyslipidaemia.
- The osteogenic effect of liraglutide involves enhanced mitochondrial biogenesis in osteoblasts.
- The mTORC1/AMPK pathway plays a role in the beneficial effects of semaglutide (GLP-1 receptor agonist) on the liver of obese mice.
- Semaglutide once weekly in people with type 2 diabetes: Real-world analysis of the Canadian LMC diabetes registry (SPARE study).
- Effects of the GLP-1 receptor agonist lixisenatide on postprandial glucose and gastric emptying--preclinical evidence.
- Safe and Effective Use of the Once Weekly Dulaglutide Single-Dose Pen in Injection-Naïve Patients With Type 2 Diabetes.
- Safety and tolerability of exenatide once weekly in patients with type 2 diabetes: an integrated analysis of 4,328 patients.
- Exenatide for weight-loss maintenance in adolescents with severe obesity: A randomized, placebo-controlled trial.
- Effects of exendin-4 alone and with peptide YY(3-36) on food intake and body weight in diet-induced obese rats.
- Incretin-based therapies for type 2 diabetes mellitus: current status and future prospects.
- The role of glucagon-like peptide-1 receptor (GLP-1R) agonists in enhancing endothelial function: a potential avenue for improving heart failure with preserved ejection fraction (HFpEF).
- Attenuation of carotid neointimal formation after direct delivery of a recombinant adenovirus expressing glucagon-like peptide-1 in diabetic rats.
- Empagliflozin and Dulaglutide are Effective against Obesity-induced Airway Hyperresponsiveness and Fibrosis in A Murine Model.
- Novel coumarin modified GLP-1 derivatives with enhanced plasma stability and prolonged in vivo glucose-lowering ability.
- The Therapeutic Potential of GLP-1 Receptor Agonists in the Management of Hidradenitis Suppurativa: A Systematic Review of Anti-Inflammatory and Metabolic Effects.